CN106518751B - Method for preparing pimavanserin - Google Patents
Method for preparing pimavanserin Download PDFInfo
- Publication number
- CN106518751B CN106518751B CN201510577381.4A CN201510577381A CN106518751B CN 106518751 B CN106518751 B CN 106518751B CN 201510577381 A CN201510577381 A CN 201510577381A CN 106518751 B CN106518751 B CN 106518751B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- carbonate
- pimavanserin
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Abstract
The invention relates to a method for preparing pimavanserin by a one-pot method. The method takes 4-isobutoxybenzylamine shown in formula (II) or salt thereof, carbonylation reagent shown in formula (III), and N- (4-fluorobenzyl) -1-methylpiperidine-4-amine shown in formula (I) or salt thereof as raw materials to prepare the pimavanserin (compound IV) by a one-pot method. The method has the advantages of high efficiency, high yield, low cost, safety and environmental protection, is suitable for industrial production and has great application value.
Description
Technical Field
The invention relates to the technical field of a preparation method of pimavanserin.
Background
Pimavanserin (pimavanserin), the chemical name of which is 1- (4-fluorobenzyl) -3- (4-isobutyloxybenzyl) -1- (1-methylpiperidin-4-yl) urea tartrate, and the structure of the free base of the tartrate is shown as the formula (I). Pimavanserin, originally developed by ACADIA pharmaceutical Inc, is a selective 5-HT2A inverse agonist and has been shown to be effective and well tolerated in the treatment of parkinson's disease psychotic disorders, and it does not block dopamine receptors and therefore does not lead to worsening of parkinson's disease symptoms.
The synthesis of pimavanserin is described in patents CN1443167 and CN 1816524.
At present, the preparation of pimavanserin by the following method is disclosed at home and abroad:
a) US2008/0280886 discloses the preparation of pimavanserin starting from methyl 4-hydroxyphenylacetate. The route is as follows:
route a) takes 4-hydroxyphenylmethyl acetate and isobutyl bromide as raw materials, and the raw materials are reacted to obtain 4-isobutoxyphenylmethyl acetate, which is hydrolyzed to obtain 4-isobutoxyphenylacetic acid, and then the 4-isobutoxyphenylacetic acid is reacted with diphenylphosphoryl azide to generate 4-isobutoxyphenylisocyanate, and finally the 4-isobutoxyphenylisocyanate is reacted with N- (4-fluorophenyl) -1-methylpiperidine-4-amine to obtain the pimavanserin free base. The method has more steps, wherein the synthesis condition of the key intermediate 4-isobutoxy phenyl isocyanate is more complex, and the used diphenyl phosphorazide is active in property, is not easy to store and is not suitable for large-scale industrial production.
b) Patent US2007/0260064 discloses a similar synthetic method and synthesizes pimavanserin.
Route b) p-hydroxybenzaldehyde and isobutyl bromide are used as raw materials to react to obtain 4-isobutoxy benzaldehyde, 4-isobutoxy benzaldehyde oxime is further synthesized, 4-isobutoxy benzylamine is obtained by reduction, 4-isobutoxy phenyl isocyanate is obtained by condensation with phosgene, and finally the p-moplanin free alkali is obtained by reaction with N- (4-fluorophenyl) -1-methylpiperidine-4-amine. The method also needs to pass through a 4-isobutoxy phenyl isocyanate intermediate process, and has more steps and more complex synthesis conditions.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the method for preparing the pimavanserin, which has the advantages of high efficiency, high yield, low cost, safety, environmental protection, suitability for industrial production and higher application value.
In order to realize the purpose, the invention uses 4-isobutoxybenzylamine or salt thereof, a carbonylation reagent and N- (4-fluorobenzyl) -1-methylpiperidine-4-amine or salt thereof as raw materials to prepare the pimavanserin by a condensation one-pot method.
The invention specifically adopts the following technical scheme:
the method for preparing the pimavanserin shown in the formula (IV) by a one-pot method is characterized in that the pimavanserin (compound IV) is prepared by the one-pot method by taking a compound shown in the formula (II), a carbonylation reagent shown in the formula (III) and a compound shown in the formula (I) as raw materials, and the reaction equation is shown as follows:
wherein:
i is N- (4-fluorobenzyl) -1-methylpiperidin-4-amine or a salt thereof;
II is 4-isobutoxy benzylamine or salt thereof;
III is a carbonylation reagent, which is selected from one or more of phosgene, chloroformic acid chloromethyl ester, bis (trichloromethyl) carbonate, N-carbonyl diimidazole, dimethyl carbonate, diethyl carbonate and p-nitro phenyl chloroformate.
In the present invention, the salts of the compounds I and II are not particularly limited, and pharmaceutically acceptable salts known in the art may be used.
Next, the present invention does not specifically require the order of the reaction of the compound of formula (II), the carbonylation reagent of formula (III) and the compound of formula (I), and it is preferred that the compound of formula (II) is used as a starting material, reacted with the carbonylation reagent of formula (III), and then reacted with the compound of formula (I) to prepare pimavanserin (compound IV) by a one-pot method.
The method for preparing the pimavanserin by the one-pot method is characterized by further comprising the step of adding alkali into the reaction.
The one-pot method for preparing pimavanserin is characterized in that the molar ratio of the compound (II) to the carbonylation reagent shown in the formula (III) is 1: (0.5 to 3.0), preferably 1: (0.5 to 2.0), more preferably 1: (0.5 to 1.5).
The one-pot method for preparing pimavanserin is characterized in that the molar ratio of the compound (II) to the compound (I) is 1.0: (0.5 to 2.0), preferably 1.0: (0.8 to 1.2), more preferably 1.0 (0.9 to 1.1).
The method for preparing the pimavanserin by the one-pot method is characterized in that the reaction temperature is-20 ℃ to the boiling point of a solvent, and the reaction time is 2.5-24 hours.
More preferably, the reaction temperature is-5 to 25 ℃ and the reaction time is 5.5 to 13 hours.
The base is not particularly limited in the present invention, and any base known in the art for converting an organic salt into a corresponding free base or neutralizing an acid generated in a condensation reaction may be used, and preferably one or a mixture of potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, lithium carbonate, silver carbonate, sodium hydrogen carbonate, potassium phosphate, sodium phosphate, potassium acetate, sodium acetate, trimethylamine, triethylamine, tributylamine, 4-dimethylaminopyridine, N, N-dimethylaniline, 1, 8-diazabicyclo [5.4.0] undec-7-ene, N-methylmorpholine, N, N-diisopropylethylamine, pyridine, 2, 6-dimethylpyridine, imidazole, N, N, N ', N' -tetramethylethylenediamine is used.
The amount of base is not particularly critical in the present invention, and any amount known in the art to convert an organic salt to the corresponding free base or to neutralize the acid produced in the condensation may be used.
The solvent for the reaction is not particularly required in the invention, and any solvent which is known in the art and can dissolve the reaction raw materials and can not react with the raw materials can be used, and one or a mixture of several of N, N-dimethylformamide, dichloromethane, chloroform, methanol, ethanol, isopropanol, butanol, tert-butanol, N-methylpyrrolidone, tetrahydrofuran, acetonitrile, 1, 4-dioxane, ethyl acetate, dimethyl sulfoxide, toluene and water is preferred.
In addition, when the compound of the formula (II) is used as a raw material, reacts with a carbonylation reagent shown in the formula (III) and then reacts with the compound of the formula (I) to prepare the pimavanserin (compound IV) by a one-pot method, the method for preparing the pimavanserin by the one-pot method is characterized in that the temperature of the compound of the formula (II) and the formula (III) is-20-25 ℃, and the reaction time is 0.5-2 hours; preferably, the temperature of the formula (II) and the formula (III) is-5 to 15 ℃, and the reaction time is 0.5 to 1 hour.
The method for preparing the pimavanserin by the one-pot method is characterized in that the reaction temperature of the pimavanserin and the formula (I) is-5-boiling point of a solvent, and the reaction time is 0.5-24 hours; preferably, the reaction temperature with the formula (I) is-5 to 25 ℃, and the reaction time is 2 to 20 hours, more preferably 5 to 12 hours.
Compared with the prior art, the invention has the following beneficial effects: the original multi-step reaction is combined into one step, the material transfer and unit operation are reduced, the production efficiency is improved, the yield is greatly improved (the yield is more than 60 percent), the production cost is reduced, and the used reagent is safe and environment-friendly.
The present invention is further illustrated by the following examples, which are intended to provide further details of the practice of the invention, but are not intended to limit the scope of the invention.
Detailed description of the preferred embodiments
Example 1: adding dichloromethane (5.0g) and 4-isobutoxybenzylamine (1.0g) into a reaction tube, cooling to 0-5 ℃, adding N, N' -carbonyldiimidazole (1.0g), keeping at 0-5 ℃ for half an hour, adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine (1.0g), stirring at 0-5 ℃ for 6 hours, heating to 22 ℃, keeping overnight (12 hours), adding water (3 multiplied by 10g), washing, taking an organic phase, concentrating to obtain a viscous oily substance, and separating white powdery solid by column chromatography (1.17g, yield 61.0%).
1H NMR:(400MHz,d-DMSO)δ:7.27-7.23(m,2H),7.13-7.09(m,2H),6.88-6.85(t,1H),6.85-6.83(m,2H),4.41(d,J＝5.6Hz,2H),3.93-3.88(m,1H),3.71(d,J＝5.6Hz,2H),2.70(d,J＝11.2Hz,2H),2.31(s,1H),2.10(s,3H),2.03-1.96(m,1H),1.90-1.85(m,2H),1.56-1.50(m,2H),1.44-1.41(m,2H),0.98(s,3H),0.96(s,3H)；
13C NMR:(100MHz,d-DMSO)δ:162.5,160.1,158.0,157.9,137.8,137.6,137.5,133.6,129.4,128.9,128.8,128.7,128.6,125.8,115.3,115.1,114.5,74.2,55.4,52.8,46.3,44.4,43.6,30.4,28.2,21.5,19.5；
MS-ESI(M+1)：428.
Example 2: dissolving 4-isobutoxybenzylamine (100.0g) in dichloromethane (500ml), cooling to 0-5 ℃, slowly adding N, N' -carbonyldiimidazole (100.0g), keeping the temperature at 0-5 ℃ for half an hour, adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine (100.0g), slowly heating to 18-22 ℃, keeping stirring for 12 hours, adding water (3 x 500g) to wash an organic phase for three times, evaporating the solvent by organic phase under reduced pressure, adding isopropyl acetate (600g), stirring for crystallization, filtering, and drying a filter cake to obtain a target product (163.0 g of white powdery solid, 85.0%).
Example 3: dissolving triphosgene (14.8g) in dichloromethane (200ml), cooling to-5 ℃, slowly and sequentially dropwise adding 4-isobutoxybenzylamine (17.9g) and triethylamine (30.3g), continuously keeping for 1 hour after adding, slowly and dropwise adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine (22.0g), slowly heating to 15-25 ℃ after adding, keeping stirring for 5 hours, washing an organic phase with water (3 x 200g) for three times, evaporating the solvent by organic phase under reduced pressure, adding isopropyl acetate (110g), stirring for crystallization, filtering, and drying a filter cake to obtain a target product (34.5 g of white powdery solid, 81.6%).
Example 4: triphosgene (14.8g) is dissolved in toluene (200ml), the temperature is reduced to-20 ℃, 4-isobutoxybenzylamine (17.9g) and triethylamine (30.3g) are sequentially and slowly added dropwise, the temperature is raised to 5 ℃ after the addition, the temperature is kept for 1 hour, N- (4-fluorobenzyl) -1-methylpiperidine-4-amine (22.0g) is slowly added dropwise, the temperature is slowly raised to 80 ℃ after the addition, the stirring is kept for 5 hours, the organic phase is washed three times by water (3 x 200g), heptane (100ml) is added into the organic phase, precipitated solid is filtered and dried, and the target product (light yellow solid powder, 21.6g, 51.0%) is obtained.
Example 5: dissolving triphosgene (14.8g) in trichloromethane (300ml), cooling to-5 ℃, adding 4-isobutoxybenzylamine hydrochloride (21.6g), slowly dropwise adding N, N-diisopropylethylamine (13.0g), continuously keeping for 1 hour after adding, slowly adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine p-toluenesulfonate (39.0g), slowly dropwise adding N, N-diisopropylethylamine (13.0g), slowly heating to 15-25 ℃ after adding, keeping stirring for 6 hours, washing an organic phase with water (3 x 200g) for three times, evaporating the solvent by organic phase under reduced pressure, adding isopropyl acetate (110g), stirring for crystallization, filtering, and drying to obtain a target product (35.2 g of white powder, 82.4%).
Example 6: dissolving 4-isobutoxy benzylamine acetate (23.9g) in dichloromethane (120ml), cooling to 0-5 ℃, slowly adding N, N' -carbonyl diimidazole (17.0g), slowly dropwise adding N, N-diisopropylethylamine (13.5g), keeping at 0-5 ℃ for half an hour after adding, adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine oxalate (26.0g), slowly dropwise adding N, N-diisopropylethylamine (13.0g), slowly heating to 15-25 ℃, keeping stirring for 10 hours, the organic phase was washed three times with water (3X 200g), the solvent was evaporated under reduced pressure from the organic phase, isopropyl acetate (110g) was added, heptane (55g) was added after stirring uniformly, and the precipitated solid was filtered and dried to obtain the objective product (37.6 g, 90.4% as a white powder).
Example 7: dissolving 4-isobutoxy benzylamine acetate (23.9g) in dichloromethane (120ml), cooling to 0-5 ℃, slowly adding p-nitrochloroformic acid phenyl ester (20.1g), slowly dropwise adding triethylamine (11.0g), keeping the temperature at 0-5 ℃ for half an hour after adding, adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine oxalate (26.0g), slowly dropwise adding triethylamine (11.0g), slowly heating to 15-25 ℃ after adding, keeping stirring for 10 hours, adding water (4 x 200g), washing an organic phase for four times, evaporating the solvent by organic phase under reduced pressure, adding ethyl acetate (100g), adding N-heptane (50g) after uniformly stirring, filtering and drying a precipitated solid to obtain a target product (32.5 g of white to light yellow powder, 78.1%).
Example 8: dissolving 4-isobutoxy benzylamine acetate (24.0g) in dichloromethane (150ml), cooling to 0-5 ℃, slowly adding N, N' -carbonyldiimidazole (17.0g), slowly dropwise adding triethylamine (11.0g), keeping the temperature at 0-5 ℃ for half an hour after adding, adding N- (4-fluorobenzyl) -1-methylpiperidine-4-amine (22.0g), slowly heating to 15-25 ℃ after adding, keeping stirring for 8 hours, adding water (3 x 200g) to wash an organic phase for three times, evaporating the solvent under the organic phase pressure, adding isopropyl acetate (100g), adding N-heptane (60g) after uniformly stirring, filtering to separate out a solid, and drying to obtain a target product (38.2 g of white powder and 90.3%).
Claims (10)
1. The method for preparing the pimavanserin shown in the formula (IV) by a one-pot method is characterized in that the pimavanserin (compound IV) is prepared by the one-pot method by taking a compound shown in the formula (II), a carbonylation reagent shown in the formula (III) and a compound shown in the formula (I) as raw materials, and the reaction equation is shown as follows:
wherein:
i is N- (4-fluorobenzyl) -1-methylpiperidin-4-amine or a salt thereof;
II is 4-isobutoxy benzylamine or salt thereof;
III is a carbonylation reagent, which is selected from one or more of chloroformic ether, bis (trichloromethyl) carbonic ester, N-carbonyl diimidazole, dimethyl carbonate, diethyl carbonate and p-nitro phenyl chloroformate.
2. The method of claim 1, further comprising adding a base to the reaction.
3. The process according to claim 1 or 2, characterized in that the molar ratio of compound (II) to carbonylation reagent of formula (III) is 1: (0.5 to 3.0).
4. The process according to claim 3, wherein the molar ratio of compound (II) to the carbonylation reagent of formula (III) is 1: (0.5 to 1.5).
5. The process according to claim 1 or 2, characterized in that the molar ratio of compound (II) to compound (I) is 1.0: (0.5-2.0).
6. The process according to claim 5, wherein the molar ratio of compound (II) to compound (I) is 1.0: (0.8 to 1.2).
7. The method according to claim 1 or 2, wherein the reaction temperature is from-20 ℃ to the boiling point of the solvent, and the reaction time is from 2.5 to 24 hours.
8. The method according to claim 7, wherein the reaction temperature is-5 to 25 ℃ and the reaction time is 5.5 to 13 hours.
9. The method according to claim 1 or 2, wherein the solvent for the reaction is selected from one or more of N, N-dimethylformamide, dichloromethane, chloroform, methanol, ethanol, isopropanol, butanol, tert-butanol, N-methylpyrrolidone, tetrahydrofuran, acetonitrile, 1, 4-dioxane, ethyl acetate, dimethyl sulfoxide, toluene and water.
10. The method of claim 2, wherein the base is selected from the group consisting of potassium hydroxide, sodium hydroxide, lithium hydroxide, potassium carbonate, sodium carbonate, cesium carbonate, lithium carbonate, silver carbonate, sodium bicarbonate, potassium phosphate, sodium phosphate, potassium acetate, sodium acetate, trimethylamine, triethylamine, tributylamine, 4-dimethylaminopyridine, N, N-dimethylaniline, 1, 8-diazabicyclo [5.4.0] undec-7-ene, N-methylmorpholine, N, N-diisopropylethylamine, pyridine, 2, 6-dimethylpyridine, imidazole, N, N, N ', N' -tetramethylethylenediamine, and mixtures thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510577381.4A CN106518751B (en) | 2015-09-11 | 2015-09-11 | Method for preparing pimavanserin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510577381.4A CN106518751B (en) | 2015-09-11 | 2015-09-11 | Method for preparing pimavanserin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106518751A CN106518751A (en) | 2017-03-22 |
| CN106518751B true CN106518751B (en) | 2021-05-04 |
Family
ID=58346650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510577381.4A Active CN106518751B (en) | 2015-09-11 | 2015-09-11 | Method for preparing pimavanserin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106518751B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111333567A (en) * | 2018-12-19 | 2020-06-26 | 北京万全德众医药生物技术有限公司 | Novel pimavanserin preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101500568A (en) * | 2006-05-15 | 2009-08-05 | 阿卡蒂亚药品公司 | Pharmaceutical formulations of pimavanserin |
| CN104844502A (en) * | 2015-06-05 | 2015-08-19 | 济南涛瑞医药科技有限公司 | Preparation method of Pimavanserin |
-
2015
- 2015-09-11 CN CN201510577381.4A patent/CN106518751B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101500568A (en) * | 2006-05-15 | 2009-08-05 | 阿卡蒂亚药品公司 | Pharmaceutical formulations of pimavanserin |
| CN104844502A (en) * | 2015-06-05 | 2015-08-19 | 济南涛瑞医药科技有限公司 | Preparation method of Pimavanserin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106518751A (en) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970123B1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| EP3645518B1 (en) | Synthesis of omecamtiv mecarbil | |
| CN102985416A (en) | Process of preparing a thrombin specific inhibitor | |
| CN102875537A (en) | Novel preparation method of antithrombosis medicine | |
| EP3668857B1 (en) | Processes for the preparation of niraparib and intermediates thereof | |
| CN105061405A (en) | Preparation method of fimasartan potassium salt hydrate | |
| CN106518751B (en) | Method for preparing pimavanserin | |
| KR20040099279A (en) | Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide | |
| CN110551144B (en) | Preparation method of amoxicillin | |
| CN111848546B (en) | 2- (aminomethyl) thiazole-5-nitrile and synthesis method thereof | |
| CN106518939B (en) | Method for preparing Solithromycin compound | |
| CN107216361B (en) | The preparation method of rope Citropten | |
| CN104910068B (en) | A kind of synthetic method of the tosilate of 2 cyano group isonicotinic acid hydrazide 1.5 | |
| CN103880756A (en) | Preparation method of azilsartan intermediate | |
| KR101557702B1 (en) | Method for the preparation of Mitiglinide Calcium Dihydrate | |
| CN101857575A (en) | Industrial preparation method of 5-methylpyrazin-2-amine | |
| JP5743474B2 (en) | Process for producing 4-amino-5-chloro-2-ethoxy-N-[[4- (4-fluorobenzyl) -2-morpholinyl] methyl] benzamide citrate dihydrate | |
| US6831178B2 (en) | Process for preparation of sulfonamide derivatives and crystals thereof | |
| US9409919B2 (en) | Process for the manufacture of spirocyclic substituted benzofuroquinolizines | |
| JP3884063B2 (en) | Cefcapene pivoxil methanesulfonate | |
| CN107216360B (en) | A method of preparing rope Citropten | |
| CN104402813A (en) | Novel method for synthesizing sorafenib | |
| CN102659713A (en) | Preparation method for cefdinir side-chain acid active ester | |
| CN110483360B (en) | Synthesis method of alfaprost alcohol | |
| CN107325092B (en) | Novel preparation process of azithromycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 210042 -18, Xuanwu Avenue, Xuanwu District, Jiangsu, Nanjing, 699 Applicant after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Applicant after: SIMCERE PHARMACEUTICAL Group Address before: 210042 -18, Xuanwu Avenue, Xuanwu District, Jiangsu, Nanjing, 699 Applicant before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Applicant before: NANJING SIMCERE DONGYUAN PHARMACEUTICA Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211206 Address after: 264006 No.1 Heilongjiang Road, Yantai Economic and Technological Development Zone, Yantai City, Shandong Province Patentee after: SHANDONG SIMCERE BIO-PHARMACEUTICAL Co.,Ltd. Patentee after: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee after: SIMCERE PHARMACEUTICAL Co.,Ltd. Address before: 210042 699 Xuanwu Road, Xuanwu District, Nanjing, Jiangsu -18 Patentee before: JIANGSU SIMCERE PHARMACEUTICAL Co.,Ltd. Patentee before: Xiansheng Pharmaceutical Co., Ltd |